Case Study- Luxturna


The ATMP Luxturna (voretigene neparvovec) is a GTMP which utilises a recombinant adeno-associated viral vector serotype 2 (rAAV2) capsid as a delivery vehicle for the human retinal pigment epithelium 65 kDa protein (hRPE65) cDNA to the retina. Luxturna is approved for patients with retinal dystrophy associated with biallelic RPE65 mutations ...

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

Not a TOPRA member yet? 

Join now to get access to:

  • Features and specialist articles
  • CPD supplements
  • Comprehensive archive

Not sure yet?  Read one of our free editorials to see what you’re missing out on!